BioSpace News Archive

Kaleido Biosciences, Inc., announced that Michael Bonney, Executive Chair, will participate in the following upcoming conferences in September.

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the H.C. Wainwright 22nd Annual Global Investment Conference.

Breadth of presentations include i) Full results from ASCENT; ii) Final results from TROPHY U-01 cohort 1; iii) First results with Trodelvy™ in brain tumors

Proceeds to support Recursion’s development of its broad clinical-stage pipeline and expansion of the capabilities of its drug discovery platform

Results show clinical study design may influence performance estimates and published sensitivity claims of SARS-CoV-2 antigen tests

Bausch Health Companies Inc. announced that Joseph C. Papa, chairman and CEO; Sam Eldessouky, senior vice president and corporate controller; and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the virtual 18th Annual Morgan Stanley Global Healthcare Conference on Sept. 16, 2020 at 1:15 p.m. ET.

Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the H.C. Wainwright 22 nd Annual Global Investment Conference, taking place virtually on Tuesday, September 15, 2020, at 2:00 p.m. ET. A live webcast of the event can be accessed i

Tauriga Sciences, Inc., a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums as well as two ongoing Biotechnology initiatives, announced that it has completed the alternative package designs for its entire Tauri-Gum™ product line.

Revolution Medicines, Inc., a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, announced that Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman, will deliver a corporate presentation as part of the H.C. Wainwright 22nd Annual Global Investment Conference.

SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, today announced that its chairman and chief executive officer, Winston Black , will participate in the 2020 Colliers Institutional Investor Conference, taking place virtually on September 10, 2020 from 9 a.m.ET to 5 p.m. ET . Mr. Black w